Effect of Coenzyme Q10 supplementation in adult patients with migraine

In adults having migraine, coenzyme Q10 may have a favorable impact on decreasing migraine attack frequency and headache duration.

To ascertain the efficacy of coenzyme Q10 (CoQ10) for reducing the severity, frequency, and duration of migraine attacks in adult migraine sufferers, a systematic review and meta-analysis was conducted.

Databases like Psychological Information Database (PsycINFO), Cumulative Index to Nursing and Allied Health Literature (CINAHL), EMBASE, MEDLINE, Cochrane Central Register of Controlled Trials, and CENTRAL were searched for randomized control trials contrasting CoQ10 with placebo or utilized as an add-on intervention. Controlled clinical studies and cross-over designs were not included. By contrasting outcomes, interventions, settings, and populations, statistical heterogeneity was assessed utilizing the I2 statistic.

For continuous outcomes, mean differences (MDs) or standardized mean differences, both with 95% CIs, were used to determine the treatment effect. Risk ratios and risk differences were used to determine the treatment effect for dichotomous outcomes. For the dosage of CoQ10 and if CoQ10 was coupled with another supplement, subgroup analyses was conducted. The influence of risk of bias on the sequence generation and allocation concealment of incorporated studies was examined using sensitivity analysis.

The meta-analysis comprised 6 trials and 371 volunteers in total. Supplementing with CoQ10 does not statistically lessen the intensity of migraine headaches. In comparison to the control group, CoQ10 supplementation decreased headache attack duration (MD: -0.19; random effects; I2 statistic = 0%). When compared to the control group, people who used CoQ10 experienced lowered frequency of migraine headache (MD: -1.52; random effects; I2 statistic = 0%).

CoQ10 use seems to be promising in lowering the duration and frequency of migraine attacks.